Cleara Biotech
founded in 2018, develops the FOXO4-DRI senolytic peptide, which disrupts the FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells.
- Country
- Netherlands
senolytic
peptide
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Geroscience & senolytics | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.